Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
